DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Jennerex
Jennerex
The Emerging Therapeutic Potential of the Oncolytic Immunotherapeutic Pexa-Vec (JX-594)
Transgene Announces a Follow-On Investment in Jennerex, Inc
Micromanaging Oncolytic Viruses
Douglas Grant Mcfadden PRESENT POSITION
Transgene Announces That Clinical Data with Pexa-Vec Will Be Presented at the 2013 American Society of Clinical Oncology Annual Meeting
Oncolytic Virotherapy As Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
Beijing Shenogen Pharma Group Limited and Lee's Pharmaceutical
Progress in Clinical Oncolytic Virus-Based Therapy for Hepatocellular Carcinoma
FOR IMMEDIATE RELEASE Jennerex and Lee's Pharmaceutical Presents
(12) Patent Application Publication (10) Pub. No.: US 2015/0037355A1 Kirn Et Al
FOR IMMEDIATE RELEASE Jennerex and Lee's Pharmaceutical Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594
Jennerex and Lee's Pharmaceutical Announce Completion Of
Transgene Announces Plans for a Phase 1B/2 Trial with Pexa-Vec in Advanced Solid Tumors
REFERENCE DOCUMENT Annual Financial Report
FOR IMMEDIATE RELEASE Jennerex and Lee's Pharmaceutical
Top View